PracticeConsultingE&Y in talks with possible Scotia buyer

E&Y in talks with possible Scotia buyer

Administrators from Ernst & Young have revealed the firm is in 'exclusive talks with a preferred bidder' for Scottish biotechnology company Scotia.

The Big Five firm said the bidder was interested in becoming a ‘future funder and development partner’.

Andrew Wollaston, one of three E&Y administrators appointed in January to run the company, said the bidder was interested in developing the drug Foscan and derivative products such as Bacteriochlorin and photodynamic therapy.

‘The bidder is a substantial enterprise with substantial resources and funding,’ Wollaston said.

E&Y took over at Scotia in January after a decision by the European Medical Evaluation Agency not to grant approval for the photdynamic drug Foscan, citing possible side-effects.

Scotia had thrown significant resources into the development of Foscan and debts had risen to Pounds 60m, forcing it into administration.

But on 28 June Scotia was thrown a lifeline when the drug regulator overturned an earlier decision to block the firm’s key drug, raising hopes that the business could be revived.

Scotia considered Foscan crucial to its long-term viability, but said today that it need more than Pounds 25m to take it to market.

Other options being considered by E&Y is Scotia raising the money for Foscan itself, forming an alliance with another pharmaceutical company, or a complete takeover by a rival group.

Whatever option is taken, Scotia will need to refinance a Pounds 50m bond issue convertible into shares at 340 pence in March 2002. When trading in Scotia shares was suspended in January they were valued at 18-1/2p, giving the plc a market cap of Pounds 16m.

In 1996, the company stock peaked at 815p.

Links

Scotia online

Related Articles

5 tips for SMEs to protect cash flow

Accounting Software 5 tips for SMEs to protect cash flow

5m Alia Shoaib, Reporter
Tyrie on Finance Bill 2017: ‘Making Tax Policy Better’

Consulting Tyrie on Finance Bill 2017: ‘Making Tax Policy Better’

11m Stephanie Wix, Writer
Managing partner Q&A - the year ahead: Richard Toone, CVR Global

Accounting Firms Managing partner Q&A - the year ahead: Richard Toone, CVR Global

12m Kevin Reed, Writer
Deloitte 'self-imposes exile' on government contracts to defuse PM row

Accounting Firms Deloitte 'self-imposes exile' on government contracts to defuse PM row

12m Kevin Reed, Writer
Managing partner Q&A - the year ahead: Julie Adams, Menzies

Accounting Firms Managing partner Q&A - the year ahead: Julie Adams, Menzies

12m Kevin Reed, Writer
Friday Afternoon Live: Deloitte's tech thing; PAC wants HMRC 'contingencies'; and Sports Direct

Business Regulation Friday Afternoon Live: Deloitte's tech thing; PAC wants HMRC 'contingencies'; and Sports Direct

1y Kevin Reed, Writer
Friday Afternoon Live: HMRC complaints rise; Deloitte scoops big audits; and corporate reporting woes

Audit Friday Afternoon Live: HMRC complaints rise; Deloitte scoops big audits; and corporate reporting woes

1y Kevin Reed, Writer
New head of equity capital markets for KPMG

Accounting Firms New head of equity capital markets for KPMG

1y Stephanie Wix, Writer